Literature DB >> 12636102

Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reaction targeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients.

S Aoki1, Y Takagi, M Hayakawa, K Yamaguchi, M Futamura, K Kunieda, S Saji.   

Abstract

Peritoneal recurrence after curative resection of malignant tumor with negative cytology is considered to be caused by microscopic dissemination of the exfoliated cancer cells from primary tumors to serosal surfaces at the time of operation, not detectable with conventional diagnostic tools. We applied the reverse transcriptase-polymerase chain reaction (RT-PCR) for carcinoembryonic antigen (CEA) and cytokeratin 20 (CK 20) to detect micrometastatic foci in the peritoneal cavity of colon cancer patients. Cytological samples taken by peritoneal lavage from a series of 79 colon cancer patients were analyzed microscopically, for CEA levels, and by RT-PCR analysis using nested primers for CEA and CK 20. Cases with both CEA and CK 20 signals were defined as PCR-positive. This RT-PCR method proved both sensitive (1 tumor cell/10(6) non-tumor cells on preparation of serial colorectal cancer cell dilutions) and specific (no false positive results, 0/23 tested in our control experiment). Intraperitoneal micrometastatic cells were detected in peritoneal lavage 7.6% by cytology, 17.7% by CEA levels, and 24.1% by RT-PCR (significantly higher than by cytology: p=0.0046). RT-PCR detection rate increased in parallel with pathological depth of tumor invasion, and also a pathological stage-dependence was suggested according to the tumor-node-metastasis classification of the International Union Against Cancer. Our results suggest that CEA and CK 20 mRNA identification by RT-PCR appeared to be reliable and may be useful for early diagnosis in peritoneal dissemination of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12636102

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  6 in total

Review 1.  Detection and clinical implications of minimal residual disease in gastro-intestinal cancer.

Authors:  Fabian Wolfrum; Ilka Vogel; Fred Fändrich; Holger Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2005-07-01       Impact factor: 3.445

2.  Lack of prognostic role of pre- and postoperative peritoneal cytology and cytokeratin PCR-expression on local recurrence after curative anterior resection for mid-low rectal cancer.

Authors:  Donato F Altomare; Michele Tedeschi; Maria-Teresa Rotelli; Domenica Bocale; Domenico Piscitelli; Marcella Rinaldi
Journal:  Updates Surg       Date:  2011-04-20

3.  Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.

Authors:  Patrick Favoulet; Laurent Benoit; Liliana Osmak; Emmanuel Polycarpe; Philippe Esquis; Christian Duvillard; Boris Guiu; Patrick Rat; Jean Pierre Favre; Bruno Chauffert
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

4.  Comparative analysis of intraperitoneal minimal free cancer cells between colorectal and gastric cancer patients using quantitative RT-PCR: possible reason for rare peritoneal recurrence in colorectal cancer.

Authors:  Masayasu Hara; Hayao Nakanishi; Qian Jun; Yukihide Kanemitsu; Seiji Ito; Yoshinari Mochizuki; Yoshitaka Yamamura; Yasuhiro Kodera; Masae Tatematsu; Takashi Hirai; Tomoyuki Kato
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

5.  Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use?

Authors:  Michael Conzelmann; Ulrich Linnemann; Martin R Berger
Journal:  Int J Colorectal Dis       Date:  2004-09-30       Impact factor: 2.571

6.  Evaluation of intraperitoneal lavage cytology before colorectal cancer resection.

Authors:  Shoichi Fujii; Hiroshi Shimada; Shigeru Yamagishi; Mitsuyoshi Ota; Chikara Kunisaki; Hideyuki Ike; Yasushi Ichikawa
Journal:  Int J Colorectal Dis       Date:  2009-05-28       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.